Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Dementia Drugs Market – Insights
Dementia is a form of disease that affects the functioning of the brain resulting in decline in memory or other thinking skills. Alzheimer’s disease is the most common and largest form of dementia (in over 60% cases), which is observed among people aged 65 years and above. Accumulation of a protein called beta amyloid in the spaces between nerve cells due to genetic mutation is a major cause of dementia. Although dementia is not treatable, symptomatic treatment is followed in all cases. Research is being carried out to develop therapies centered on the role of beta-amyloid in dementia.
The global dementia drugs market was valued at US$ 13,900.0 million in 2017 and is expected to witness a CAGR of 8.4% over the forecast period (2018–2026).
Figure 1. Global Dementia Drugs Market Value (US$ Mn) Forecast and Absolute $ Opportunity (US$ Mn)
Source: Coherent Market Insights Analysis (2018)
Increasing number of pipeline products is expected to drive growth of the dementia drugs market
Major factor fueling growth of the dementia drugs market includes, increasing number of drugs in the pipeline, which are expected to enter into the market by 2020-2022. According to the study published by Translational Research and Clinical Intervention, in September 2017, 105 new drugs are in pipeline, out of which 25 are in phase one, 52 in phase two, and 28 in phase three. These new products use novel approaches such as immunotherapy to target amyloid beta, beta-site amyloid precursor protein cleaving enzyme 1 inhibitors, tau aggregation inhibitor, and serotonin 5-HT6 receptor antagonist. Furthermore, increasing collaborations amongst companies for developing drugs in joint efforts is also boosting growth of the market. For instance, in November 2017, Novartis and Amgen, along with the Banner Alzheimer's Institute, announced a collaboration to assess potential of the BACE1 inhibitor CNP520 to prevent or delay symptoms of Alzheimer's disease.
However, failure of investigational candidate in late stage is expected to be a huge setback in the market. For instance, in February 2017, an external data monitoring committee warned that Merck & Co., Inc. terminated study of Alzheimer's candidate verubecestat due to potential failure in a Phase II/III study.
Increasing incidence of Alzheimer’s disease worldwide is expected to drive growth of the dementia drugs market. According to World Alzheimer Report in 2016, around 46.5 million people were suffering from Alzheimer’s disease, the number for which is projected to reach 50 million by 2017. Increasing geriatric population is also a major risk factor for growing incidence of Alzheimer’s disease, which in turn boosts growth of the dementia drugs market. For instance, according to World Population Prospects (WPP) published by United Nations in 2017, around 962 million people aged 60 years and above were recorded, which accounted for 13 percent of the global population. The number is projected to reach 1.4 billion by 2030, exhibiting annual growth rate of 3 percent. Europe accounts for the largest geriatric population (25% of population) in 2017. Asia Pacific also had geriatric population of 547 million people in 2017 and is projected to reach 900 million by 2025. These regions thus show potential opportunity for growth of the market.
Dementia Drugs Market Regional Outlook - Growing Integration of Healthcare and IT to boost demand in emerging economies
On the basis of geography, the global dementia drugs market can be segmented into six major regional markets: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to account for the largest market share, owing to major approval of drugs in this region and favorable reimbursement scenarios. Asia Pacific is expected to emerge as a major market in the near future, majorly due to the growing geriatric population and Alzheimer’s disease cases, especially in China and India. For instance, according to Alzheimer’s Disease International Association, in 2015, East Asia recorded the maximum number of people living with dementia (9.8 million), followed by Western Europe (7.4 million).
Key players are adopting strategic collaboration, acquisition, and product portfolio expansion to enhance their market share. For instance, Teva Pharmaceutical Industries Ltd. acquired Actavis Generics from Allergan in 2016, for around US$ 40 billion, which also includes the Alzheimer’s portfolio of Actavis Generics. This acquisition boosted revenue of Teva in its fourth quarter of 2016 and first quarter of 2017. Furthermore, Genentech and AC Immune are also jointly developing anti-amyloid beta antibody crenezumab, which started phase three clinical trial in 2017. They are developing anti-amyloid beta vaccine for Alzheimer’s disease treatment. Furthermore, AC Immune and Janssen Pharmaceutical are also co-developing vaccine for Alzheimer’s treatment.
Some of the top companies operating in the dementia drugs market are Eisai, Inc., Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc.., Valeant Pharmaceutical International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd.